Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Laura is the vice president of content for 

) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Articles

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

AML Survival After 3 Years in Remission Comparable With General Population

Sabrina McCrear is an assistant editor for 

 (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for 

Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on 

The American Heart Association (AHA) launched a news initiative to address challenges with in-hospital care for patients with different types of heart failure. 

AHA Launches New Initiative to Help Patients With Heart Failure

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

CSU More Burdensome in Female Patients, Especially in Midlife

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting. 

Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1rem

Topic

 speaks with Julia Lucaci, PharmD, MS, the senior director of global health economics and outcomes research at Becton, Dickinson and Company (BD), an international medical technology company.

, "Should Payers Incentivize Pharmacies to Blister-Package Chronic Medications?", argues that payers should consider offering higher reimbursement rates and/or preferred network status to pharmacies that dispense chronic medications in blister packs to enhance medication adherence and patient outcomes.

During the conversation, Lucaci explores the widespread impact of medication nonadherence, the benefits and underutilization of blister packaging in the US, and strategies that could support broader adoption to improve chronic disease management and lower overall health care costs.

Listen above or on one of these podcast services:

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

On this episode of Managed Care Cast, we’re talking with the co–editors in chief of 

), Mark Fendrick, MD, and Michael Chernew, PhD. They look back on the research and news that stood out to them from the past year and discuss what they’re looking forward to in 2025 as the journal celebrates its 30th anniversary.

Screening for Health Literacy, Social Determinants, and Discrimination in Health Plans

Privately Negotiated Facility Fees at Ambulatory Surgery Centers and Hospitals

Also, please take a look at our dedicated page featuring our efforts to celebrate AJMC’s 

The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.

AJMC® Editors Reflect on 2024 and Look Forward to a Milestone

On this episode of Managed Care Cast, we're talking with the University of Pennsylvania's Ravi Parikh, MD, MPP, and Aaron Schwartz, MD, PhD, 2 authors of a study published in the April 2024 issue of 

"Trends in Low-Value Cancer Care During the COVID-19 Pandemic,"

 discusses how rates of low-value cancer services among adults with newly diagnosed cancer persisted throughout the COVID-19 pandemic.

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.


Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

This is the final episode of Oncology Onward for 2023.

Oncology Onward: A Conversation With Penn Medicine's Justin Bekelman, MD

On this final Oncology Onward episode of 2023, cohosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, talk with Penn Medicine’s Justin Bekelman, MD,

director of the Penn Center for Cancer Care Innovation. Their conversation encapsulates much of what has been discussed in the oncology space in the past year, from the unique perspective of academic medicine: the importance of collaboration between academic medical centers and community oncology practices and testing innovative cancer care delivery in academic and community settings to have the greatest impact on patients.

“If we can only show that a certain innovation works at Penn Medicine or an academic practice, it's very limited—it's useful, but it's very limited,” Bekelman says. “If we want to demonstrate as part of our mandate to generalize knowledge across the country, we have to be able to extend programs into the community, learn from the community, test things that are working in the community in academic environments, create a bidirectional approach that allows for expertise from both systems to create the best possible opportunities for patients with cancer.”

Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.

Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman

Drs Emeline Aviki and Stephen Schleicher speak with Robin Shah of Thyme Care

Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah

On our fourth episode of Oncology Onward, Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, sit down for a conversation with Robin Shah, MBA, cofounder and CEO of Thyme Care, which he started in 2020 with Bobby Green, MD, president and chief medical officer.

A biomedical engineer by education, Shah spent the first 5 years of his professional career as practice administrator and business manager at Gettysburg Cancer Center, working with his father, a community oncologist. From there, he moved to Flatiron Health and in July of 2017, helped to found OneOncology. Thyme Care was founded in July of 2020, and in August of this year 

 a successful $60 million Series B round of investment capital.

, this entrepreneur in oncology care innovation has been guided by a patient-first mentality and the principal goal of positively changing how patients experience the cancer care system.

Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system. 

Florida Cancer Specialists & Research Institute's (FCS') Nathan Walcker, CEO, discusses some key strategic practices and initiatives in providing high quality community-based oncology care he has implemented at FCS.

®’s Institute for Value-Based Medicine® event held in Tampa, Florida, on August 10, 2023.

Listen above or through one of these podcast services:

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective. 

Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS

Drs Emeline Aviki and Stephne Schleicher speak with Jef Patton, MD, CEO of OncOncology

Oncology Onward: A Conversation With OneONcology's Dr Jeff Patton

Jeff Patton, MD, CEO and board member of 

 and executive chairman of Tennessee Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, for episode 3 of, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Patton, also chairman of the Community Oncology Alliance and a board-certified hematologist and 

, highlights of the origins of OneOncology that it was created to protect community oncology, to give other states and communities the opportunity to stay independent in light of large hospital systems, if they wanted to. He also discusses the importance of community clinical trial accrual and of keeping oncological services within the community and not handing them over to large hospital systems, thereby driving up the cost of care. 

“OneOncology was created by physicians for physicians to maintain the autonomy and allow physicians the choice of seeing patients in the community vs in a hospital or academic medical center,” he emphasizes. “I think every patient, every family deserves choice. In many cases, and in most cases, we feel like the community option is the best.”

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Oncology Onward: A Conversation With OneOncology’s Dr Jeff Patton 

AJMC.com recently launched a resource center, the 

, dedicated to promoting education, advocacy, and best practices for improving health outcomes and reducing health disparities for all.

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion (DEI) advancing health equity in their respective organization’s policy and practice initiatives, including:

Gregory Vidal, MD, PhD, director of Clinical Research at West Cancer Center & Research Institute

Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

Health Equity Conversations: Managing Underserved Communities and Value-Based Payment

On this episode of Managed Care Cast, we bring you part 1 of an 8-part video conversation with a payer and a primary health care provider about how they adapted to deliver health care in 2020 and 2021. We sat down with Tunde Sotunde, MD, MBA, the president and CEO of Blue Cross and Blue Shield of North Carolina, the largest insurer in that state covering more than 3.7 million members across all 100 counties, and Alan Story, MD, of Newtown Family Physicians, an independent primary care practice in Catawba County in the western part of the state.

Our conversation, moderated by Allison Inserro, managing editor of AJMC.com, the website of 

delves into value-based care, independent care practices, the health care workforce, health equity, and the role of Medicaid.

Impact of Value-Based Care on Primary Care

Health Care Consolidation and Independent Practices

Health Equity and Social Determinants of Health

SAP Partners

On this episode of Managed Care Cast, we bring you part 1 of an 8-part video conversation with Blue Cross Blue Shield of North Carolina and Newton Family Physicians about how they adapted to deliver health care in 2020 and 2021.

Primary Care During COVID-19: Looking at Payer, Provider Cooperation

On this episode of Managed Care Cast, we’re talking with the co-editors-in-chief of 

®, Mark Fendrick, MD, and Michael Chernew, PhD, and the editor-in-chief of 

®, Dennis Scanlon, PhD. They look back on the past year and discuss the themes and topics they expect to see in the pages of the journals and in the world of health care in 2022.

The editors of The American Journal of Managed Care® and The American Journal of Accountable Care® reflect on the past year and discuss the themes and topics they expect to see in 2022.

Looking Ahead to 2022 With the Editors of AJMC®

On July 9, 2025, experts from across Providence Health & Services gathered in Garden Grove, California, for in-depth discussions on patient-centered care for chronic diseases.

Safeguarding Patient Health Through Value-Based Systems Integration

Community oncology leaders navigate challenges in value-based care under the Enhancing Oncology Model, facing performance payment uncertainties and evolving drug markets.

Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move

Remote Clinical Pharmacists Saved Nearly $9M, Helped Practices Meet EOM Targets

Explore how payers and providers collaborate to enhance value-based care, tackle rising costs, and improve patient outcomes in today's health care landscape.

Payers and Providers Seek Common Ground on Costs, Technology, and Value-Based Care 

Given the track record of good outcomes and savings, policy leaders must do more to promote growth of for-profit PACE programs, the author asserts.

PACE Program Expansion Requires For-Profit Investment, Reduced Regulatory Burden, and Greater Patient Eligibility

Dr Matias Sanchez on Impactful Developments in Myeloma Care and How to Optimize Delivery

The shift from broad chemotherapy regimens to targeted treatments, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, has improved overall survival and quality of life for patients with 

, but implementing processes that ensure proper use of novel therapies is key for health systems and providers.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health and assistant professor of medicine in the Division of Hematology and Oncology at the University of Illinois College of Medicine, discussed major developments in multiple myeloma management and how health systems can support value-based, patient-centered care. Optimal myeloma management in the era of effective—and expensive—therapies was the topic of a session at a recent 

This transcript has been lightly edited for clarity; captions are auto-generated.

What new developments in multiple myeloma treatment have made the biggest impact on day-to-day practice in recent years?

Myeloma, I think, is one of the most interesting cancers that has had more developments than most other cancers recently. But I would say the use of minimal residual disease [MRD] in these patients, that's very important because we can tailor therapies in terms of giving them transplant. Most likely, for example, patients who are MRD negative will not need transplant, or we don't give them so much maintenance therapy if they're MRD negative; that's one thing. The use of MRD is one important thing. 

But definitely the bigger winner is the use of the CAR T-cell therapies and the use of bispecifics—immunotherapy—that we've seen big, the best responses that we've never had in multiple myeloma. And there's a line of investigation that we're having there that will definitely continue to improve, so we're excited.

How can health systems and providers support value-based, patient-centered care for multiple myeloma?

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.

Value-Based Care

Latest News